Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ (RIT 90YEpra)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01354457
Recruitment Status : Unknown
Verified May 2011 by Nantes University Hospital.
Recruitment status was:  Active, not recruiting
First Posted : May 16, 2011
Last Update Posted : June 25, 2014
Information provided by (Responsible Party):
Nantes University Hospital